About SynDevRx

SynDevRx is based in Cambridge Massachusetts. Our team has decades of experience in drug development. Our goal is to develop novel compounds that target MetAP2 in a formulation-dependent way, and commercialize them through partnerships with industry leaders.

Here at SynDevRx, we believe that success comes from a balanced combination of leading technology and talented people with synergistic skills. The combination of our best-in-class technology, thought leaders in clinical oncology, senior drug development professionals and creative marketing executives with fresh perspectives promises to deliver high value solutions to patients and investors alike.

Unlocking The Value Of MetAP2

MetAP2 is a unique, validated target, and has many scientists' attention.  In 2008, researchers announced that MetAP2 is possibly a newly-defined oncogene, thereby elevating its importance with respect to cancer treatments.  Yet, until this generation of technology, finding a suitable compound that safely and selectively targets MetAP2 has proven to be elusive.

Combining a well characterized molecule clinically proven to have exclusive, high affinity for MetAP2 with a nano-transport polymer is a rational approach to drug delivery.  The fact that each of these components has been in humans previously reduces the risks and greatly increases the likelihood of success.

Click here for an Executive Summary on SynDevRx.